Until now, no studies have directly compared the predictive efficiency of exosomal PD-L1 with other clinical tumor markers, and some studies have found that exosomal PD-L1 cooperating with other tumor markers or immune modulators (such as CD28), may be a better predictive biomarker than exosomal PD-L1 alone [134]. This evidence concerns the gene CD274 and neoplasm.